Home > Healthcare > hairy cell leukemia market
Get a free sample of Hairy Cell Leukemia Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Hairy Cell Leukemia Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The hairy cell leukemia industry comprises companies such as Amgen Inc, AstraZeneca, F. Hoffmann-La Roche Ltd, and Merck KGaA. These are significant players, with well-established product portfolios. Companies adopt several inorganic growth strategies to maintain their market share.
Prominent players operating in the hairy cell leukemia industry include:
Hairy cell leukemia market size was USD 130.7 million in 2023 and is expected to register 6.5% CAGR from 2024-2032 owing to the increasing incidence rates of blood related cancers, advancements in diagnosis and rare disease treatment options, and emerging oncology therapies worldwide.
Asia Pacific hairy cell leukemia industry garnered 43.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of a large population and high incidence of leukemia cases in the region.
The chemotherapy segment held 65.2% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being a standard treatment offer and acting as a first-line therapy for newly diagnosed HCL patients.
Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., and Takeda Pharmaceutical Company Limited, are some of the major hairy cell leukemia companies worldwide.